Meeting
2011 ASCO Annual Meeting
Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).
Authors
J. J. Vredenburgh
Duke University Medical Center, Durham, NC
J. J. Vredenburgh , A. Desjardins , D. A. Reardon , K. Peters , J. Kirkpatrick , A. D. Coan , L. Bailey , D. Janney , C. Lu , H. S. Friedman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01004874
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2098)
Abstract #
2098
Poster Bd #
8H
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
First Author: Martha Nowosielski
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2013 ASCO Annual Meeting
Survival benefit from bevacizumab in newly diagnosed glioblastoma (GBM) according to transcriptional subclasses.
First Author: Jason T. Huse
Poster
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
First Author: Martin Kelly Nicholas